Document 1127
 DOCN  M94A1127
 TI    The efficacy of zidovudine in AIDS patients in Brazil.
 DT    9412
 AU    Sprinz E; Kronfeld M; Sfair A; Hospital de Clinicas Porto Alegre (HCPA),
       Brazil.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(2):202 (abstract no. PB0820). Unique
       Identifier : AIDSLINE ICA10/94371448
 AB    OBJECTIVE: Study the efficacy and safety of low doses of zidovudine
       (ZDV) in recently diagnosed AIDS patients in Brazil. PATIENTS & METHODS:
       Since July 1989 HIV patients willing to take part on research trials are
       being enrolled at HCPA, a national AIDS Reference Center in the south of
       Brazil. We analyze 128 patients from initial AIDS diagnosis (according
       to the CDC revisited criteria) to death, who have taken or not ZDV, 300
       to 600 mg daily. Pregnancy, life expectancy less than 4 months or
       inability to follow orders were the exclusion criteria. ZDV group (677
       patients willing to take the drug) is compared to the non-drug group
       (655 patients not willing to take ZDV). The groups were comparable in
       age, sex and AIDS index diagnosis. RESULTS: Four patients in ZDV and 5
       in non-drug group were lost to follow-up. ZDV was well tolerated, but 8
       patients (12%) had to discontinue the drug (independent of ZDV dose): 6
       with severe bone marrow toxicity and 2 due to gastrointestinal
       intolerance. The mean survival time was 20 months in ZDV group (dose
       independent) and 12.5 months in non-ZDV group (p < 0.001). CONCLUSIONS:
       This is the first brazilian study on low doses of ZDV. ZDV was
       relatively safe and well-tolerated and increased the survival time of
       patients with AIDS. We strength the need of controlled studies using
       these doses of ZDV either alone or in association with other antiviral
       drugs.
 DE    Acquired Immunodeficiency Syndrome/*DRUG THERAPY  Human  Support,
       Non-U.S. Gov't  Zidovudine/ADMINISTRATION & DOSAGE/ADVERSE
       EFFECTS/*THERAPEUTIC  USE  CLINICAL TRIAL  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).